Does Markedly Active Bone Marrow Proliferation Indicate Leukemia?

Bone marrow hypercellularity—meaning an abnormally increased number of hematopoietic cells in the bone marrow—is not, by itself, diagnostic of leukemia. It is a nonspecific finding observed in a wide range of clinical conditions, including reactive states such as infections, chronic inflammation, bleeding, hemolytic anemias, and recovery from cytopenias. While certain types of leukemia—particularly acute myeloid leukemia (AML) and chronic myeloid leukemia (CML)—can present with hypercellular marrow, many patients with leukemia actually exhibit normocellular or even hypocellular marrow, especially in cases with extensive fibrosis or prior therapy.

Diagnosing leukemia requires integration of multiple lines of evidence: morphologic assessment of peripheral blood and bone marrow aspirate smears, flow cytometric immunophenotyping, cytogenetic analysis (e.g., karyotyping, FISH), and molecular testing (e.g., detection of *BCR::ABL1*, *FLT3*, *NPM1*, or *CEBPA* mutations). The presence of ≥20% blasts in the bone marrow—or ≥20% in peripheral blood for AML—is a key diagnostic criterion per WHO and ICC classifications. In contrast, benign causes of hypercellularity typically show preserved maturation across lineages without blast excess or dysplasia.

Clinicians must therefore interpret bone marrow cellularity within the full clinical and laboratory context—including symptoms (e.g., fatigue, fever, bruising), complete blood count abnormalities (cytopenias or cytoses), peripheral blood smear findings, and ancillary test results. Relying solely on cellularity can lead to misdiagnosis; conversely, overlooking subtle morphologic or immunophenotypic abnormalities in a seemingly “normal” marrow may delay critical intervention.